Navigation Links
Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
Date:12/19/2007

Avastin offers patients the chance to live twice as long without their

disease advancing

BASEL, Switzerland, Dec. 19 /PRNewswire/ -- Avastin (bevacizumab), Roche's innovative anti-cancer drug, was approved today in Europe for the first-line treatment of patients with advanced renal cell cancer (RCC) in combination with interferon (IFN), the current standard of care*. Kidney cancer, known as renal cell carcinoma (RCC) is a disease that kills over 100,000 people per year world-wide(1).

There are few early symptoms in kidney cancer which means that unfortunately the majority of patients are diagnosed with advanced disease, where current treatment options are limited. Kidney cancer is highly resistant to chemotherapy and radiotherapy, which are often key weapons against other cancer types(2).

The approval was based on data from the pivotal phase III AVOREN trial, which showed that patients with advanced RCC who received Avastin in combination with IFN lived nearly twice as long without their disease progressing ("progression free survival"), as those who received IFN alone.

"The results of the AVOREN study confirmed that Avastin is a safe, effective and well tolerated treatment option for patients with advanced renal cell cancer," said Professor Bernard Escudier, Head of the Immunotherapy and Innovative Therapy Unit, Institut Gustave-Roussy, Paris, France and Principal Investigator of the pivotal AVOREN study. "Avastin effectively doubles the time in which patients live without their disease getting worse, so this approval has the potential to change the treatment landscape for this disease, where treatment options are still limited."

Avastin Approval Status

Kidney cancer is the fourth cancer type in which Avastin has demonstrated positive survival benefits for patients. Data from the comprehensive Avastin cancer clinical development programme have resulted in approvals in advanced colorectal, breast, lung, and now kidney cancer:
-- February 2004 (US) and January 2005 (EU) - first-line treatment in

patients with metastatic colorectal cancer (CRC)

-- June 2006 (US) - second-line treatment in patients with metastatic CRC

-- October 2006 (US) - first-line treatment in patients with advanced non

small cell lung cancer (NSCLC)

-- March 2007 (EU) - first-line treatment in patients with metastatic

breast cancer

-- April 2007 (Japan) - treatment in patients with recurrent or advanced

CRC

-- August 2007 (EU) - first-line treatment in patients with advanced NSCLC

-- December 2007 (EU) - first-line treatment in patients with advanced RCC

About the AVOREN Study

The AVOREN study is a randomised, controlled, double-blind, phase III study that included 649 patients with advanced kidney cancer from 101 study sites across 18 countries. Study participants received treatment with either Avastin and IFN alpha-2a or placebo and IFN alpha-2a, the standard of care in patients with advanced kidney cancer.
The results of the AVOREN trial showed that by adding Avastin to IFN:

-- Progression free survival (PFS) was almost doubled from a median of 5.4

to 10.2 months

-- Tumour response was significantly increased from 12.8% with IFN alone

to 31.4% when Avastin was added

-- Dose-reduction of IFN did not appear to affect the efficacy of the

combination with Avastin (based on PFS event free rates over time, as

shown by a sub-group analysis)

The study also showed a trend towards improved overall survival; however, these data are still pending. No new or unexpected adverse events were observed.

An interim analysis of AVOREN was performed in December 2006 and the benefits provided by Avastin were so positive that the Drug Safety Monitoring Board recommended that the trial was unblinded and all patients were offered treatment with Avastin. The study demonstrated for the first time that Avastin benefits patients in combination with an immunotherapeutic, the class of drugs to which IFN belongs.

*The approval is for the use of Avastin in patients with advanced and/or metastatic RCC in combination with IFN.

References

1. Parkin DM, Bray F, Ferlay J and Pisani P. 2002. CA Cancer J Clin, 2005; 55: 74-108.

2. De Mulder, PHM. Ann Oncol, 2007; 18 (Supplement 9): ix98-ix102.


'/>"/>
SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
2. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
3. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
4. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
5. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
8. Medpace Strengthens Presence in Central Europe
9. Kline Study: Better Brushing Habits Boost European Oral Care Sales
10. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
11. European Centre for Modern Drug Discovery Established in Hamburg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... NY (PRWEB) , ... October 12, 2017 , ... ... of Sciences today announced the three Winners and six Finalists of the 2017 ... given annually by the Blavatnik Family Foundation and administered by the New York ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... States multicenter, prospective clinical study that demonstrates the accuracy of the FebriDx® ... identifying clinically significant acute bacterial and viral respiratory tract infections by testing ...
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global ... industries to improve patient outcomes and quality of life, will now be offering ... being attributed to new regulatory requirements for all new drug products, including the ...
(Date:10/11/2017)... Charlotte, N.C. (PRWEB) , ... October 11, 2017 ... ... ARCS® Foundation President Andi Purple announced Dr. Suneel I. Sheikh, the ... Laboratories ( ASTER Labs ), Inc. has been selected for membership in ...
Breaking Biology Technology:
(Date:8/23/2017)... 2017  The general public,s help is being enlisted in what,s thought ... in and on the human body –and are believed to affect health.  ... The Microbiome Immunity Project is the ... with the gut. The project's goal is to help advance scientific knowledge ... ...
(Date:7/20/2017)... July 20, 2017 Delta (NYSE: DAL ) customers ... Delta aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics to board aircraft ... Delta,s biometric boarding pass ... is now integrated into the boarding process to allow eligible Delta ...
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017 ... a leader in dairy research, today announced a new ... help reduce the chances that the global milk supply ... this dairy project, Cornell University has become the newest ... Food Supply Chain, a food safety initiative that includes ...
Breaking Biology News(10 mins):